29th November 2011

Further data to be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

Following Richmond Pharmacology’s Chief Executive Officer and Principal Investigator Dr Jorg Taubel’s presentation at the recent 2nd DIA Cardiac Safety Workshop in Japan, further data will be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), taking place 1st to 3rd December 2011, at Act City Hamamatsu.

This year’s annual scientific meeting will assess the latest trends in clinical pharmacology and, as a first, will be jointly hosted by the three societies of the Japanese Society of Clinical Pharmacology and Therapeutics (JPCPT), the Korean Society of Clinical Pharmacology and Therapeutics (KSCPT) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

Dr Taubel’s poster presentation session will provide an update on the original research carried out by Richmond Pharmacology, and is scheduled for Thursday, 1st December between 14:15 and 15:10:

• Alternative Methods for the Confirmation of Assay Sensitivity in Thorough QT Studies (Program number: 1-P-77)
  
  
• QT Prolongation in Healthy Japanese Subjects Receiving Moxifloxacin in Thorough QT Studies (Program number: 1-P-78)
  
  
• Sex Differences of the Effect of Moxifloxacin  - A Meta -analysis of Five thorough QT Studies (Program number:  1-P-79)

Our total success rate in all Thorough QT studies reported to date confirms that we are a leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.

For further information on our cardiac safety expertise and other specialist services please speak to a company representative at booth number 5, where we will be available to discuss how Richmond can benefit your prospective Phase I/II study requirements.

We look forward to seeing you in Tokyo.

24th October 2011

Accelerating Early Phase Clinical Development in the UK:

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) welcomes you to attend its annual meeting being held on Friday 18th November at the Wellcome Collection Conference Centre, London from 13h30 to 17h30.

The Association has been in existence for over nearly 2 decades and has forged links with both other scientific societies with similar interests and with professional bodies such as the ABPI and ICR. The AHPPI's mission is to offer a framework for discussion and to exchange on current topics in applied Human Pharmacology and early phase drug development. Its aim is also to provide training, education and guidance and provide a forum for innovation and the development of new methods and efficiencies.

The topic of this meeting will focus on "Accelerating Early Phase Clinical Development in the UK", and as always we expect to have a panel of excellent speakers from such organisations as ABPI, MHRA, NHS, pharmaceutical and CRO industries. For further details for what's in store for the day, please click here to view the full meeting agenda or here to register.

Furthermore there will be the opportunity to attend the guided tours of the Wellcome collections and exhibitions. If you are interested in attending a tour on the day of the AHPPI meeting, please contact us for more details.

This meeting has been awarded four Continuing Professional Development points by the Faculty of Pharmaceutical Medicine and is open to AHPPI members and non-members.  On behalf of the AHPPI we cordially invite you to attend and look forward to seeing you next month!